As a CDMO, Emergent has been working for more than two decades to develop, manufacture and deliver protections against public health threats and deliver vaccines and therapeutic products for clients. In it's work with biopharma and biotechnology businesses, as well as government and nongovernment organizations, Emergent provides the technology, expertise and talent to help quickly and efficiently ramp up manufacturing and development for its clients' products.
During COVID-19, Emergent deployed new processes, and technologies to manufacture novel coronavirus vaccine and therapeutic candidates for CDMO clients. That experience has doubled as a learning opportunity for the future. In this article, Emergent team members reflect on lessons learned through COVID-19 and share four consideration to help prepare for the next public health threat.